The 1550 on the Green tower will anchor a new mixed-use district. Rendering courtesy of Skanska

A new office tower will soon loom over the popular Discovery Green as the anchor of a new downtown district. Global development and construction firm, Skanksa, announced the new building at 1550 Lamar St. and its anchor tenant on January 13. The new 28-story, 375,000-square-foot Class-A office structure is dubbed 1550 on the Green, per a Skanska statement.

Global law firm Norton Rose Fulbright will relocate its Houston office in 2024 and acquire naming rights upon occupancy, according to a press release.

Bound by La Branch, Lamar, Crawford, and Dallas Streets, 1550 on The Green will feature extra-wide pedestrian zones with a canopy of trees, two tenant outdoor roof terraces, and wide views of the surrounding greenery.

International design firm BIG-Bjarke Ingels Group led the building's design; it is the company's first foray into Texas. BIG's design promises sustainability, energy efficiency, and an "airy" office environment for tenants, a release describes.

Some 7,000 square feet of retail space will greet first-floor guests. Michael Hsu Office of Architecture has been tapped to design the interior amenity spaces; those include a fitness center, rooftop event space and terrace, and community spaces.

The new 1550 on the Green tower is part of a new envisioned district that will be branded as Discovery West. The district will consist of 3.5 acres of mixed-use development boasting restaurants, retail, green space, and "world-class architecture," per a release.

Working with Central Houston Inc., Discovery Green, Bike Houston, the Kinder Foundation, as well as several brokers, Skanska and design firm of record, BIG-Bjarke Ingels Group, completed the master plan for Discovery West in early 2020.

Skanska has been noticeably active in the Houston office market, specifically with the development of Bank of America Tower, West Memorial Place I and II, and the future Discovery West. The company is behind the acquisition of a buzzy strip center in Montrose. Skanska also plans to multifamily to its Houston portfolio, the firm notes.

"As an organization that prides itself on building what matters to our communities, our team, made up of Houstonians, has been working alongside local stakeholders to develop a plan and a building that will transform this side of downtown Houston while still meeting the needs of the city," said Matt Damborsky, executive vice president for Skanska USA commercial development's Houston market, in a statement.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”